# US 2021/0261674 A1 · Anti-IL1RAP Antibodies and Their Use for Treating Humans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261674 A1
- Document ID: US20210261674A1
- Status: Published application
- Kind: A1
- Application number: 17/241,609
- Filed: 2021-04-27
- Published: 2021-08-26
- Earliest claimed: 2011-01-19
- Assignees: Cantargia AB
- Applicants: Cantargia AB
- Inventors: Thoas Fioretos; Marcus Järås
- Web page: https://patentgrep.com/patent/US20210261674A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1033: {against receptors for cytokines, lymphokines or interferons}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumour, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.

## Claims

### Claim 1

An agent comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP.

### Claim 2 (depends on 1)

An agent according to claim 1 for use in treating or preventing a solid tumour in a patient.

### Claim 3

An agent comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting cells associated with a solid tumour, wherein the cells express IL1RAP.

### Claim 4 (depends on 1, 2, 3)

An agent according to any one of claims 1 to 3 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas.

### Claim 5

An agent according to any one of the preceding claims wherein the solid tumour is selected from the group consisting of cancers of the prostate, breast, skin, colon, lung, urinary organs and uterus.

### Claim 6

An agent according to any one of the preceding claims wherein the solid tumour is selected from the group consisting of prostate cancer, melanomas, cervical cancer, oesophageal cancer, and head and/or neck cancer.

### Claim 7 (depends on 1, 2, 3)

An agent according to any one of claims 1 to 3 wherein the solid tumour is a melanoma.

### Claim 8

An agent according to any one of the preceding claims wherein the binding moiety has specificity for human IL1RAP.

### Claim 9

An agent according to any one of the preceding claims wherein IL1RAP is localised on the surface of a cell.

### Claim 10

An agent according to any one of the preceding claims wherein the agent is capable of blocking binding of one or more co-receptors to IL1RAP.

### Claim 11 (depends on 10)

An agent according to claim 10 wherein the one or more co-receptors are selected from the group consisting of IL1R1, ST2, C-KIT and IL1RL2.

### Claim 12

An agent according to any one of the preceding claims wherein the agent is capable of killing the cells associated with the solid tumour.

### Claim 13 (depends on 12)

An agent according to claim 12 wherein the agent is capable of inducing apoptosis of the cells associated with the solid tumour.

### Claim 14 (depends on 12, 13)

An agent according to claim 12 or 13 wherein killing of the cells is induced by antibody-dependent cell-mediated cytotoxicity (ADCC).

### Claim 15

An agent according to any one of the preceding claims wherein the agent comprises or consists of a polypeptide.

### Claim 16 (depends on 15)

An agent according to claim 15 wherein the agent comprises or consists of an antibody or an antigen-binding fragment thereof with binding specificity for IL1 RAP, or a variant, fusion or derivative of said antibody or antigen-binding fragment, or a fusion of a said variant or derivative thereof, which retains the binding specificity for IL1RAP.

### Claim 17

An agent according to any one of the preceding claims wherein the agent comprises or consists of an antibody or antigen-binding fragment thereof.

### Claim 18 (depends on 17)

An agent according to claim 17 wherein the agent comprises or consists of an intact antibody.

### Claim 19 (depends on 17)

An agent according to claim 17 wherein the agent comprises or consists of an antigen-binding fragment of an antibody.

### Claim 20 (depends on 19)

An agent according to claim 19 wherein antigen-binding fragment is selected from the group consisting of Fv fragments (e.g. single chain Fv, disulphide-bonded Fv and domain antibodies) and Fab-like fragments (e.g. Fab fragments, Fab′ fragments and F(ab)2 fragments).

### Claim 21 (depends on 16, 17, 18, 19, 20)

An agent according to any one of claims 16 to 20 wherein the antibody is a recombinant antibody.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

An agent according to any one of claims 16 to 21 wherein the antibody is a monoclonal antibody.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21)

An agent according to any one of claims 16 to 21 wherein the antibody is a polyclonal antibody.

### Claim 24

An agent according to any one of the preceding claims wherein the antibody or antigen-binding fragment thereof is human or humanised.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

An agent according to any one of claims 1 to 15 wherein the agent comprises or consists of a non-immunoglobulin binding moiety.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

An agent according to any one of claims 1 to 15 wherein the agent comprises or consists of an aptamer.

### Claim 27 (depends on 26)

An agent according to claim 26 wherein the agent comprises or consists of a peptide aptamer.

### Claim 28 (depends on 26)

An agent according to claim 26 wherein the agent comprises or consists of a nucleic acid aptamer.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

An agent according to any one of claims 1 to 14 wherein the agent comprises or consists of a small chemical entity.

### Claim 30

An agent according to any one of the preceding claims further comprising a moiety for increasing the in vivo half-life of the agent.

### Claim 31 (depends on 30)

An agent according to claim 30 wherein the moiety for increasing the in vivo half-life is selected from the group consisting of polyethylene glycol (PEG), human serum albumin, glycosylation groups, fatty acids and dextran.

### Claim 32 (depends on 30, 31)

An agent according to claim 30 or 31 wherein the agent is PEGylated.

### Claim 33

An agent according to any one of the preceding claims further comprising a cytotoxic moiety.

### Claim 34 (depends on 33)

An agent according to claim 33 wherein the cytotoxic moiety comprises or consists of a radioisotope.

### Claim 35 (depends on 34)

An agent according to claim 34 wherein the radioisotope is selected from the group consisting of astatine-211, bismuth-212, bismuth-213, iodine-131, yttrium-90, lutetium-177, samarium-153 and palladium-109.

### Claim 36 (depends on 33)

An agent according to claim 33 wherein the cytotoxic moiety comprises or consists of a toxin (such as saporin or calicheamicin).

### Claim 37 (depends on 33)

An agent according to claim 33 wherein the cytotoxic moiety comprises or consists of a chemotherapeutic agent (such as an antimetabolite).

### Claim 38

An agent according to any one of the preceding claims further comprising a detectable moiety.

### Claim 39 (depends on 38)

An agent according to claim 38 wherein the detectable moiety comprises or consists of a radioisotope.

### Claim 40 (depends on 39)

An agent according to claim 39 wherein the radioisotope is selected from the group consisting of: technitium-99m; indium-111; gallium-67; gallium-68; arsenic-72;
zirconium-89; iodine-12 ; thallium-201.

### Claim 41 (depends on 38)

An agent according to claim 38 wherein the detectable moiety comprises or consists of a paramagnetic isotope

### Claim 42 (depends on 41)

An agent according to claim 41 wherein the paramagnetic isotope is selected from the group consisting of: gadolinium-157; manganese-55, dysprosium-162, chromium-52; iron-56.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A pharmaceutical composition comprising an effective amount of an agent as defined in any one of claims 1 to 42 and a pharmaceutically-acceptable diluent, carrier or excipient.

### Claim 44 (depends on 43)

A pharmaceutical composition according to claim 43 adapted for parenteral delivery.

### Claim 45 (depends on 43)

A pharmaceutical composition according to claim 43 adapted for intravenous delivery.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A kit comprising an agent as defined in any one of claims 1 to 42 or a pharmaceutical composition as defined in any one of claims 43 to 45.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

Use of an agent as defined in any one of claims 1 to 42 in the preparation of a medicament for inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP.

### Claim 48 (depends on 47)

The use according to claim 47 wherein the medicament is for use in treating or preventing a solid tumour in a patient.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

Use of an agent as defined in any one of claims 1 to 42 in the preparation of a diagnostic agent for detecting cells associated with a solid tumour, wherein the cells express IL1RAP.

### Claim 50 (depends on 47, 48, 49)

The use according to any one of claims 47 to 49 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas.

### Claim 51 (depends on 50)

The use according to claim 50 wherein the solid tumour is selected from the group consisting of cancers of the prostate, breast, skin, colon, lung, urinary organs and uterus.

### Claim 52 (depends on 50)

The use according to claim 50 wherein the solid tumour is selected from the group consisting of prostate cancer, melanomas, cervical cancer, oesophageal cancer, and head and/or neck cancer.

### Claim 53 (depends on 47, 48, 49)

The use according to any one of claims 47 to 49 wherein the solid tumour is a melanoma.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour in an individual, comprising the step of administering to the individual an effective amount of an agent as defined in any one of claims 1 to 42, or a pharmaceutical composition as defined in claims 43 to 45, wherein the cells express IL1RAP.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for detecting cells associated with a solid tumour in an individual, comprising the step of administering to the individual an effective amount of an agent as defined in any one of claims 1 to 42, or a pharmaceutical composition as defined in claims 43 to 45, wherein the cells express IL1RAP.

### Claim 56 (depends on 54, 55)

A method according to claim 54 or 55 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas.

### Claim 57 (depends on 56)

The method according to claim 56 wherein the solid tumour is selected from the group consisting of cancers of the prostate, breast, skin, colon, lung, urinary organs and uterus.

### Claim 58 (depends on 56)

The method according to claim 56 wherein the solid tumour is selected from the group consisting of prostate cancer, melanomas, cervical cancer, oesophageal cancer, and head and/or neck cancer.

### Claim 59 (depends on 54, 55)

A method according to claim 54 or 55 wherein the solid tumour is a melanoma.

### Claim 60

An agent for use in medicine substantially as described herein with reference to the description.

### Claim 61

A pharmaceutical composition substantially as described herein with reference to the description.

### Claim 62

Use of an agent substantially as described herein with reference to the description.

### Claim 63

A method of treatment or diagnosis as described herein with reference to the description.

### Claim 64

A kit substantially as defined herein with reference to the description.
